# TargEDys

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/targedys

- Industry: Healthcare
- Headquarters: Paris, France
- Website: www.targedys.com
- Total disclosed funding: $4.2M
- Latest round: Series A (May 24, 2016)
- Investors on record: 3

## About

TargEDys SA is a health solutions company focused on enhancing gut health and overall well-being through innovative microbiome modulation products.Founded in 2011 and headquartered in Paris, France, TargEDys SA specializes in health solutions aimed at improving gut health. The company has not undergone any notable pivots or operational changes since its inception. Sergueï Fetissov, the founder, has previously engaged in health-related enterprises. TargEDys has completed a total of 4 deals, with its most recent fundraising event being a Series A round on September 18, 2019, raising EUR 4.164 million, which corresponds to the total amount raised. The current valuation of TargEDys is EUR 15.769 million.TargEDys specializes in innovative health solutions aimed at enhancing gut health and overall well-being through its core offerings in microbiome modulation. The company provides a range of products designed to address various health challenges, focusing on improving digestive health, weight management, and metabolic support. TargEDys' flagship products work by harnessing the power of probiotics and prebiotics, which are essential for maintaining a balanced gut microbiota. These products target consumers seeking effective nutritional support to improve their metabolic functions and digestive processes. TargEDys serves a diverse client base, including health-conscious individuals and healthcare professionals, and markets its products across various regions, including Europe and North America, ensuring accessibility to a broad audience looking for gut health solutions.In the most recent fiscal year, TargEDys generated revenue of EUR 1,875,544.40, with an EBITDA of EUR -842,618.30. The company generates revenue through a combination of direct sales and partnerships with retailers and healthcare providers, engaging in direct-to-consumer sales as well as B2B arrangements with health and wellness retailers and pharmacies.TargEDys is focused on expanding its product offerings, including the development of new formulations aimed at enhancing metabolic health, with planned releases in the upcoming year. The company aims to penetrate new markets, particularly in North America and Asia, by the end of 2024. The recent Series A funding of EUR 4.16 million will support these initiatives, allowing TargEDys to invest in product development and market entry strategies.

## Funding rounds

- Series A, May 24, 2016, $4.2M — Seventure Partners, Pontifax Venture Capital, NCI

## Investors

- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series A
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series A
- NCI (https://capitalatlas.ai/funds/nci) — Series A